These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7159063)

  • 1. Blink rates in parkinsonism.
    Karson CN; LeWitt PA; Calne DB; Wyatt RJ
    Ann Neurol; 1982 Dec; 12(6):580-3. PubMed ID: 7159063
    [No Abstract]   [Full Text] [Related]  

  • 2. Blink reflex in Parkinson's disease with levodopa-induced dyskinesia.
    Iriarte LM; Chacon J; Madrazo J; Chaparro P
    Funct Neurol; 1989; 4(3):257-61. PubMed ID: 2792861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (4) Dyskinesia caused by levodopa].
    Mano T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):877-8. PubMed ID: 1035530
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical physiology of dopa dyskinesia.
    Hallett M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa addiction in idiopathic Parkinson disease.
    Borek LL; Friedman JH
    Neurology; 2005 Nov; 65(9):1508. PubMed ID: 16275855
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies to modify levodopa treatment.
    Widner H
    Adv Neurol; 2003; 91():229-36. PubMed ID: 12442681
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of levodopa effects by internal pallidal stimulation.
    Krack P; Pollak P; Limousin P; Hoffmann D; Benazzouz A; Benabid AL
    Mov Disord; 1998 Jul; 13(4):648-52. PubMed ID: 9686769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-induced dyskinesia and thalamotomy.
    Narabayashi H; Yokochi F; Nakajima Y
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):831-9. PubMed ID: 6381653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
    Linazasoro G
    Arch Neurol; 2007 Jan; 64(1):137-40. PubMed ID: 17210824
    [No Abstract]   [Full Text] [Related]  

  • 17. Blink reflex in dyskinetic and nondyskinetic patients with Parkinson's disease.
    Iriarte LM; Chacon J; Madrazo J; Chaparro P; Vadillo J
    Eur Neurol; 1989; 29(2):67-70. PubMed ID: 2707294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.